European Psychiatry
March 1, 2023
V. W. L. Tsang, R. Moyer, P. Kryskow et al.
2 citations
IntroductionHealthcare practitioners (HCPs) are facing a mental health crisis. Group therapies have long been used to treat symptoms associated with PTSD, anxiety and/or depression, however no studies have investigated the role of implementing group therapy with and without ketamine-assisted therapies (KaT).ObjectivesThe current study investigated the effects of the Roots to Thrive (RTT) group...
Psychedelics as Psychiatric Medications
March 1, 2023
Michael C Mithoefer, David E. Presti
Abstract MDMA (3,4-methylenedioxymethamphetamine) was originally synthesized and patented by the Merck chemical company in 1914. It was not explored for human use until the 1970–80s when there were published reports that it could be a useful catalyst to psychotherapy, in part because it often produced reduced anxiety and increased emotional openness. In 1985, in response to media attention to...
European Psychiatry
March 1, 2023
V. W. L. Tsang, Brendan Tao, Shannon Dames et al.
1 citation
IntroductionKetamine has been increasingly used to treat mental health conditions yet there is a lack of safety data on intramuscular (IM) and sublingual (SL) dosing in a community setting. The Roots to Thrive Ketamine assisted Therapy (RTT-KaT) program is a 12-week program with 12 Community of Practice (CoP) group therapy sessions and three ketamine sessions.ObjectivesTo provide preliminary...
Culture, Medicine, and Psychiatry
March 1, 2023
Robert Colbert, Shannon Hughes
16 citations
Within the modern resurgence of psychedelics as medicinal agents for a range of conditions, the story of MDMA (Ecstasy, Molly) has been re-narrated from a dangerous street drug to a breakthrough mental health therapy. Even still, the story of MDMA remains incomplete within a binary discourse of deviant recreational use versus psychotherapeutic-medical use. The present research aimed to uncover...
PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie
March 1, 2023
Anne Karow
1 citation
Psychedelische Substanzen haben sich über die letzten Jahre überraschend zu neuen Hoffnungsträgern für eine Verbesserung des Therapieerfolgs in der Behandlung verschiedener psychischer Erkrankungen entwickelt. Auslöser für die Renaissance psychedelischer Therapien waren nicht allein pharmakologische Innovationen der letzten Jahre, sondern auch eine steigende Ratlosigkeit angesichts...
Psychological Medicine
March 1, 2023
Isabel Wießner, Marcelo Falchi, Fernanda Palhano-Fontes et al.
53 citations
For a century, psychedelics have been investigated as models of psychosis for demonstrating phenomenological similarities with psychotic experiences and as therapeutic models for treating depression, anxiety, and substance use disorders. This study sought to explore this paradoxical relationship connecting key parameters of the psychotic experience, psychotherapy, and psychedelic experience. In...
Psychedelic Medicine
March 1, 2023
Lucas Dwiel, Angela Henricks, Elise Bragg et al.
4 citations
Psychedelic drugs have resurged in neuroscience and psychiatry with promising success in psychedelic-assisted therapy for the treatment of anxiety, depression, and addiction. At the cellular level, psychedelic drugs elicit neuroplastic processes 24 h after administration, priming neural circuits for change. The acute effects of psychedelic drugs are well characterized with functional imaging...
IntechOpen eBooks
February 24, 2023
Gita Vaid
1 citation
Our chapter traces the origins of the psychoanalytic method back to experiences of non-ordinary states of consciousness achieved through the practice of hypnosis. Psychedelic medicines have the capacity to reveal hidden aspects of the unconscious mind that include symbolic elements and early organizational structures that correspond to Freud’s primary process thinking and which underpin...
Neuropsychopharmacology
February 20, 2023
Gabriela Garza, Bita Moghaddam, Alejandro Torrado Pacheco et al.
69 citations
Abstract Psilocybin has been shown to improve symptoms of depression and anxiety when combined with psychotherapy or other clinician-guided interventions. To understand the neural basis for this pattern of clinical efficacy, experimental and conceptual approaches that are different than traditional laboratory models of anxiety and depression are needed. A potential novel mechanism is that acute...
Psychiatric News
February 16, 2023
Jacques Ambrose, Jeffrey S Zabinski
With the impending FDA review of the phase 3 data for MDMA-assisted psychotherapy for PTSD, experts reflect on ethical considerations, appropriate use, and access. The groundswell of interest in psychedelics in psychiatry, medicine broadly, and in popular culture continues without a peak in sight. Though the term “psychedelic” was coined in the 20th century, these compounds have an extensive...